Thromboembolic events during thalidomide treatment
| . | DVT/PE incidence without thromboprophylaxis . | DVT/PE incidence with thromboprophylaxis . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Newly diagnosed patients, % . | Reference . | Relapsed/refractory patients, % . | Reference . | Fixed low-dose warfarin, % . | Full-dose warfarin, % . | Aspirin, % . | LMWH, % . | Reference . | |
| Thalidomide alone | 3 | 30 | 2-3 | 10,12 | ND | ND | ND | ND | — |
| Thalidomide plus dexamethasone | 12-26 | 31-34 | 2-7 | 17,19 | 12-25 | 8 | ND | ND | 15,32,35,36 |
| Thalidomide plus melphalan | 6-20 | 37-39 | 4-11 | 21,22 | ND | ND | ND | 3 | 37 |
| Thalidomide plus doxorubicin | 10-27 | 40-42 | 58* | 43 | 12-14 | ND | 14-18 | 5-9 | 24,43,,–46 |
| Thalidomide plus cyclophosphamide | 3*-11 | 47,48 | 2-8 | 27-29 | 12 | ND | ND | ND | 26 |
| Thalidomide plus multiagent chemotherapy | 16-34 | 49,50 | 15 | 15 | 31 | ND | ND | 15-24 | 49,51 |
| . | DVT/PE incidence without thromboprophylaxis . | DVT/PE incidence with thromboprophylaxis . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Newly diagnosed patients, % . | Reference . | Relapsed/refractory patients, % . | Reference . | Fixed low-dose warfarin, % . | Full-dose warfarin, % . | Aspirin, % . | LMWH, % . | Reference . | |
| Thalidomide alone | 3 | 30 | 2-3 | 10,12 | ND | ND | ND | ND | — |
| Thalidomide plus dexamethasone | 12-26 | 31-34 | 2-7 | 17,19 | 12-25 | 8 | ND | ND | 15,32,35,36 |
| Thalidomide plus melphalan | 6-20 | 37-39 | 4-11 | 21,22 | ND | ND | ND | 3 | 37 |
| Thalidomide plus doxorubicin | 10-27 | 40-42 | 58* | 43 | 12-14 | ND | 14-18 | 5-9 | 24,43,,–46 |
| Thalidomide plus cyclophosphamide | 3*-11 | 47,48 | 2-8 | 27-29 | 12 | ND | ND | ND | 26 |
| Thalidomide plus multiagent chemotherapy | 16-34 | 49,50 | 15 | 15 | 31 | ND | ND | 15-24 | 49,51 |
PE indicates pulmonary embolism; ND, not determined; and —, not applicable.
Includes newly diagnosed and relapsed patients.